FDA's Unique Device Identification (UDI) System

Jay Crowley
Senior Advisor for Patient Safety
Food and Drug Administration
jay.crowley@fda.hhs.gov
301-796-5995

FDA Amendments Act of 2007

September 27, 2007, the FDAAA signed into law:

The Secretary shall promulgate regulations establishing a unique device identification system for medical devices requiring the label of devices to bear a unique identifier, unless the Secretary requires an alternative placement or provides an exception for a particular device or type of device. The unique identifier shall adequately identify the device through distribution and use, and may include information on the lot or serial number.

Date Format

- If label includes a date (expiration, manufacture):
- Presented as Month Day, Year (JAN 1, 2012)
- All dates must include a day (JAN 2012 not allowed)
- The month shown as a three letter abbreviation in capital letters: e.g., JAN, FEB, MAR
- Day is an number from 1-31
- Year is a 4 digit number

Effective 1 year after final rule publication

Establishing a UDI System

- 1. Combination of 4 distinct steps:
- 2. Develop a standardized system to develop the unique device identifiers (UDI)
- 3. Place the UDI in human readable and/or AutoID on a device, its label, or both
- 4. Create and maintain the UDI Database
- 5. Adoption and Implementation

- Develop UDI code according to ISO 15459 [issuing agencies like GS1, HIBCC]
- Created and maintained by the manufacturer
- Concatenating Device and Production Identifier
- Device Identifier (DI): [static] Manufacturer, make, model [i.e., each catalogue number]
- Production Identifier (PI): [dynamic] however product is currently controlled serial, lot number; expiration, manufacturing date

2nd – UDI Application

- Unique UDI applied to all levels of packaging, down to the lowest level (patient use/unit of use)
- Default location is the label
- Human readable and encoded in a form of automatic identification technology
- No specific technology (technology neutral)
- ALSO Direct Part Marking (DPM) for
 - an implantable device (>30 days)
 - intended to be used more than once, and intended to be sterilized before each use
 - stand-alone software

General Exemptions (1/2)

- Class I devices are not required to have production identifiers in UDI
- Devices, other than prescription devices, made available for purchase at a retail establishments.
- GMP-exempt Class I devices
- Individual class I, single-use devices, all of a single version or model, that are distributed together in a single device package, which are not intended for individual sale the UDI is on the package

General Exemptions (2/2)

- Devices used for research, teaching, or chemical analysis, and not intended for any clinical use
- Custom devices within the meaning of 812.3(b)
- Investigational devices (part 812)
- Veterinary devices not intended for human use
- Devices intended for export from the US
- Device held by the Strategic National Stockpile
- Devices which FDA has established a performance standard and has included an UDI exception
- Shipping containers

Prestige(TM) LP Cervical Disc 6x12mm Mat'I: TITANIUM CARBIDE COMPOSITE

12mm 6mm x Size:





Medtronic

PRESTIGE® Cervical Disc System CERVICAL DISC, 6X12MM Size: 6mm x 12mm

Mat'I: TITANIUM CARBIDE COMPOSITE

Sterility assured only when package is undamaged.

REF 6972260

123456789

Use By: 2222/11/11

QTY: 1 EA



Medtronic Sofamor Danek USA, Inc. 1800 Pyramid Place Memphis, Tennessee 38132 Telephone 800 933 2635 (in

U.S.A.) 901 396 3133 (Outside U.S.A.) Fax 901 396 0356

Manufactured in WARSAW IN US











(€0123

PRINT_RUN_TYPE(PLANT_NAME)USER_INITIALS082211



Finger-Mounted Locking Forceps

REF FMF02

LOT 1Q34

□ 080100

QTY 4

(01) 2 081019001 002 4

(17)080100(10)1Q34



(E₀₃₄₄

Manufacturer

T.A.G. Medical Products Kibbutz Gaaton 25130 Israel Tel: 972-4-9858400, Fax: 972-4-9858404



EU representative

MEDNET GmbH

Borkstrasse 10 48163 Muenster, Germany

Tel: +49 (251) 32266-0 Fax: +49 (251) 32266-22



Distributor

Ethicon Endo-Surgery Inc Cincinnati OH 45242-2839 USA



Do not use if package is open or damaged

STERILE R



Single patient use only

PVC

Does not contain latex or




Finger-Mounted Locking Forceps



REF FMF





www.crbard.com PK5019915 / Rev. 5 /10-2009


for use

Combination Products and Kits

- Like other devices intended to facilitate identification:
- Combination product (PMOA is a device) has its own UDI; each device constituent needs its own UDI.
 - Except a CP that is physically, chemically, or otherwise combined with other parts of the CP such that it is not possible for the device constituent to be used except as part of the use of the CP.
- Each kit (devices only) has its own UDI; each device packaged in a convenience kit shall have its own UDI, distinct from the kits.
 - Except a device is intended for a single use does not need its own UDI

3rd – Global UDI Database

- Device Identifier Type/Code [GTIN, HIBCC]
- Make/model; Brand/Trade Name
- Clinically relevant size
- Device version/model number (or reference number)
- Unit of Measure/Packaging level/quantity
- Controlled by Lot and/or Serial Number; Exp. Date
- Labeler contact name, phone, email
- GMDN Classification code/term
- Whether packaged sterile
- Contains latex
- FDA premarket authorization (510k, PMA)
- Listing number



4th – Implementation

- Based on premarket risk class:
 - class III 12 months after final rule (implants)
 - class II 36 months after final rule (equipment)
 - class I 60 months after final rule (disposables)
- Direct part marking requirements are effective 2 years after class effective date
- Phase out national numbering system (NDC/NHRIC)

• Submit comments electronic or written comments on the proposed rule by [INSERT DATE 120 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

- You may submit comments, identified by Docket No. FDA-2011-N-0090 and/or RIN No. 0910-AG31, by any of the following methods, except that comments on information collection issues under the Paperwork Reduction Act of 1995 must be submitted to the Office of Regulatory Affairs, Office of Management and Budget (OMB) at FAX: 202-395-7285, or e-mail comments to OIRA_submission@omb.eop.gov.
- Please mark your comments to the attention of the FDA desk officer and reference this rule.

What's Next?

- FDA will consider all comments submitted.
- Final Rule Coming Soon
- Implementation
- Training Stakeholders (Industry & Healthcare Professionals)

- www.fda.gov/UDI
- dsmica@fda.hhs.gov or 1-800-638-2041
- cdrhudi@fda.hhs.gov